Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin-Reference-Cited by-同舟云学术

Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin

Published:1980-04 Issue:2 Volume:8 Page:165-176
ISSN:0090-466X
Container-title:Journal of Pharmacokinetics and Biopharmaceutics
language:en
Short-container-title:Journal of Pharmacokinetics and Biopharmaceutics

Author:

Boxenbaum Harold

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics

Link

http://link.springer.com/content/pdf/10.1007/BF01065191.pdf

Reference35 articles.

1. L. B. Mellett. Comparative drug metabolism.Prog. Drug Res. 13:136–169 (1969).

2. M. Weib, W. Sziegoleit, and W. Förster. Dependence of pharmacokinetic parameters on the body weight.Int. J. Clin. Pharmacol. 15:572–575 (1977).

3. K. B. Bishoff, R. L. Dedrick, D. S. Zaharko, and J. A. Longstreth. Methotrexate pharmacokinetics.J. Pharm. Sci. 60:1128–1133 (1971).

4. U. Klotz, K.-H. Antonin, and P. R. Bieck. Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat.J. Pharmacol. Exp. Ther. 199:67–73 (1976).

5. B. B. Brodie. Of mice, microsomes and man.Pharmacologist 6:12–26 (1964).

Cited by 326 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk assessment of N‐nitrosamines in food;EFSA Journal;2023-03

2. Establishing allometric relationships between microsomal protein and cytochrome P450 content with body weight in vertebrate species;Toxicology;2023-03

3. Surgical Models of Liver Regeneration in Pigs: A Practical Review of the Literature for Researchers;Cells;2023-02-13

4. Comparison of toxicokinetic properties of eleven analogues of Bisphenol A in pig after intravenous and oral administrations;Environment International;2023-01

5. EFSA Pilot Project on New Approach Methodologies (NAMs) for Tebufenpyrad Risk Assessment. Part 1. Development of Physiologically‐Based Kinetic (PBK) Model Coupled With Pulmonary and Dermal Exposure;EFSA Supporting Publications;2023-01